Silihan lan utang jangka dawa perusahaan: Cocrystal (COCP)

Current price action for Cocrystal Pharma, Inc. (COCP) demonstrates long-term debt at 0.00, highlighting the business's independence from market volatility due to the demand for medical products. Cocrystal Pharma, Inc. (COCP) relies on the expansion of small molecules to combat COVID-19 and influenza, utilizing X-ray crystallography. Growth is based on the creation of agents that are mutation-resistant and effective against resistant forms of infections, including norovirus.

This indicator measures the aggregate of credit obligations with maturities exceeding one year, allowing for an assessment of the liability structure's stability and the risks of interest overpayments during refinancing. An analysis of the long-term debt capital of Cocrystal Pharma, Inc. (COCP) demonstrates the company's financial reliability, as its investments in the development of universal antiviral drugs require balanced financing to ensure operational stability during its active growth phase.